Development of anti-p185HER2 immunoliposomes for cancer therapy.

The product of the HER2 protooncogene, p185HER2, represents an attractive target for cancer immunotherapies. We have prepared anti-p185HER2 immunoliposomes in which Fab' fragments of a humanized anti-p185HER2 monoclonal antibody with antiproliferative properties (rhuMAb-HER2) were conjugated to...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Park, J W, Hong, K, Carter, P, Asgari, H, Guo, L Y, Keller, G A, Wirth, C, Shalaby, R, Kotts, C, Wood, W I
Médium: Artigo
Jazyk:Inglês
Vydáno: 1995
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC42512/
https://ncbi.nlm.nih.gov/pubmed/7877976
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky